



Lexaria Bioscience Corp.

CSE:LXX | OTCQX:LXRP

Lexaria Bioscience has developed a new disruptive drug delivery platform: DehydraTECH™

The Company's patented technology changes the way Active Pharmaceutical Ingredients ("APIs") enter the body orally:

- 1) **Masks unwanted tastes** – eliminates the need for sugar-filled edibles.
- 2) **Reduces time of onset** – effects are felt within 15-20 min vs. 60-120 min.
- 3) **Avoids first-pass liver metabolism** – mitigating unwanted side effects.
- 4) **Increases bio-absorption up to 5-10X** - to equate absorption by inhalational delivery.



The Company's DehydraTECH™ technology is **patent-protected** for multiple APIs:

Cannabidiol (CBD), Tetrahydrocannabinol (THC),
Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen,
Nicotine,
Fat soluble vitamins.



Business Model:

- 1) **Out-license (royalty)** the technology to third-party partners / distributors. Range: 5-10% of gross sales.
- 2) **Product Sales** - Lexaria sells hemp oil **CBD** (cannabidiol) products. **ViPova™** branded premium teas deliver CBD in several flavors. **TurboCBD™** hemp oil capsules are formulated with Ginseng & Ginkgo for enhanced focus and memory.

Growing Patent Portfolio – ~50 patent applications filed in US, International (under the Patent Cooperation Treaty), and national filings in 44 countries. Patents include both method and composition of matter claims. **Patents issued** in USA, Australia: "Food and beverage compositions infused with lipophilic active agents and methods of use thereof".

Research Agreements with **National Research Council** and other laboratories to investigate opportunities associated with bioavailability enhancement of lipophilic active ingredient, and research on additional DehydraTECH™ applications.

2018 research program showed DehydraTECH™ delivered **225% increase in penetration of CBD topical skin creams**. *In-vivo* (in-animal) lab tests showed **5X more nicotine in brain tissue**. Nicotine edibles do not currently exist due to nicotine's inability to pass through the human GI tract without irritation. DehydraTECH™ may offer a disruptive alternative to this \$990B market, which is aggressively pursuing cigarette alternatives.

Key Executives:

Chris Bunka - Chairman & CEO.

Serial entrepreneur, extensive experience in the capital markets, corporate governance, M&A and finance.

John Docherty, M.Sc. - Director & President.

20 yr. senior executive in the pharmaceutical and bioscience M.Sc. in pharmacology and B.Sc. in toxicology from the University of Toronto.

Mr. Ted McKechnie – Director.

Senior entrepreneurial executive with extensive senior management & board experience in the consumer goods industry in National and Retail brands. Former President and COO of Maple Leaf Foods.


Stock Information:

Trading symbol: CSE:LXX, OTCQX:LXRP

Shares o/s: 72m, (f/d: 83m)

Mgmt & Insiders: 15m (21%)

Recent price: C\$2.40 / US\$1.80



For more information, contact Alex Blanchard, Communications Manager: (778) 796-1897, Email: ABlanchard@lexariabioscience.com